Context: The LENAddOn study aimed to: characterize PWH initiating injectable lenacapavir (LEN) post-early access program in France; assess LEN continuation rates at W26 and W52; describe reasons for LEN discontinuation. Methods: Observational, retrospective study across 19 centers, including people with HIV-1 who initiated LEN between 20/06/2023 and 30/06/2024. Socio-demographic, clinical, and laboratory data were extracted from medical records. The primary outcome was the proportion of PWH receiving a second and third set of LEN injections at W26 and W52. Results: 77 PWH were included (median age 57 years [IQR 44-63]; duration of ART 25 years [17-29]), with a history of frequent adherence issues and vulnerability factors. At LEN initiation, 22 (28.6%) had a plasma HIV-1 viral load (pVL) ≥200 copies/mL and 43 (55.8%) a pVL <50 copies/mL; 42 (54.6%) had viral resistance to ≥2 drugs in ≥3 classes. 21 participants (27.3%) received injectable ART associating LEN plus cabotegravir ± rilpivirine. LEN continuation rate was 94.8% (95% CI 87.2-98.6) at W26, and 81.8% (71.4-89.7) at W52, with 4 LEN discontinuations between D0 and W26, and 10 between W26 and W52. Main reasons for LEN discontinuation were: death unrelated to LEN/lost-to-follow-up (n=5), persistence of viral replication (n=3) and injection site reactions (ISRs, n=2). Last measured pVL during the study period was <200 cp/mL in 72/77 participants (93.5%), and <50 cp/mL in 61/77 (79.2%). Conclusion: LEN use allowed simplification of antiretroviral regimens, with the maintenance or achievement of virological suppression. Continuation of LEN at W26 and W52 remained high among a population with extensive treatment history.